CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study.

导出 LinkOut

翻译打印收藏纠错

第一作者： Guoqing,Wei

第一单位： Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, No.79 Qingchun Road, Hangzhou, China.

作者： Guoqing,Wei ^[1] ; Yongxian,Hu ^[1] ; Chengfei,Pu ^[2] ; Jian,Yu ^[1] ; Yi,Luo ^[1] ; Jimin,Shi ^[1] ; Qu,Cui ^[3] ; Wenjun,Wu ^[1] ; Jinping,Wang ^[2] ; Lei,Xiao ^[2] ; Zhao,Wu ^[4] ; He,Huang ^[5]

作者单位： Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, No.79 Qingchun Road, Hangzhou, China. ^[1] Innovative Cellular Therapeutics Co., Ltd., Room 201, Building 4, 998 Halei Road, Shanghai, 201203, China. ^[2] Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. ^[3] Innovative Cellular Therapeutics Co., Ltd., Room 201, Building 4, 998 Halei Road, Shanghai, 201203, China. wuzhao@sidansai.com. ^[4] Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, No.79 Qingchun Road, Hangzhou, China. huanghe@zju.edu.cn. ^[5]

关键词 Acute lymphoblastic leukemia Chimeric antigen receptor T cells Refractory/relapsed